|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$3,729,754
|
N/A
|
National Institutes of Health
|
|
|
Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)
|
261201500018I
|
$2,155,216
|
$2,155,216
|
-, -
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
IGF::OT::IGF Topic 378: mPROS: Mobile PRO-CTCAE Administration System for Post-Radiation Toxicities
|
261201800013C
|
$224,995
|
$112,498
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
|
IGF::OT::IGF SBIR Topic 374, Phase I:Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention
|
261201800026C
|
$300,000
|
$300,000
|
-, -
|
THERANANO, LLC
|
|
|
Topic 375: Novel Diagnostic Imaging Modality for Monitoring Tumor Responses to a Hyperthermia Immunotherapy - Moonshot
|
261201800028C
|
$40,573
|
$40,573
|
-, -
|
IMAGO SYSTEMS, INC.
|
|
|
IGF::OT::IGF
|
261201800038C
|
$1,499,993
|
$1,499,993
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
|
NATIONAL FOOD AND NUTRIENT ANALYSIS PROGRAM (NFNAP) DIETARY NUTRIENTS
|
ACN18004-001
|
$225,000
|
$78,750
|
-, -
|
UNITED STATES DEPT OF AGRICULTURE
|
|
|
NCHS SMALL AREA EST
|
APC18002-001
|
$50,000
|
$12,500
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
$56,265
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
5UM1CA186704-04
|
$1,703,461
|
$562,142
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
|
Postmenopausal women's alcohol study
|
ZIA CP000101 10336
|
$951
|
$714
|
Abnet, Christian
|
DCEG (NCI)
|
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-04
|
$401,456
|
$401,456
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
Li-Fraumeni Syndrome in Brazil
|
ZIA CP010144 10769
|
$53,072
|
$26,536
|
Achatz, Maria Isabel
|
DCEG (NCI)
|
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
$107,524
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
$67,374
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
|
Evaluating mass spectrometry for intraoperative tissue characterization in breast-conserving therapy
|
5R01CA201469-03
|
$406,031
|
$406,031
|
AGAR, NATHALIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer
|
1R01CA213996-01A1
|
$343,125
|
$343,125
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$29,071
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$184,440
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Assessment of sensory gating, attention, and executive control in breast cancer
|
1R01CA218496-01A1
|
$687,576
|
$687,576
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
$155,289
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
$299,607
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
|
Vitamin D Pooling Project
|
ZIA CP010195 10436
|
$47,159
|
$11,790
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Study of Weight Change in Breast Cancer Patients Receiving Adjuvant Chemotherapy
|
ZIA CP010197 10350
|
$15,920
|
$15,920
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$305,909
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
|
Lymphatic and systemic immunity changes in post-radiation lymphedema development
|
5R01CA201487-03
|
$357,343
|
$357,343
|
ALDRICH, MELISSA
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
|
p63 as a novel factor promoting pregnancy-induced HER2-positive breast cancer
|
5K22CA190653-03
|
$157,743
|
$157,743
|
ALEXANDROVA, EVGUENIA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
|
Inherited bone marrow failure syndromes study
|
ZIA CP010144 07130
|
$1,652,758
|
$33,055
|
Alter, Blanche
|
DCEG (NCI)
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$8,550
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$12,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$158,735
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
$223,893
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
5R01CA208042-03
|
$363,713
|
$363,713
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$399,760
|
$399,760
|
Ambs, Stefan
|
CCR (NCI)
|
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$112,963
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
|
Role of histone kinase VprBP in gene silencing: mechanisms, targets, and regulation
|
5R01CA201561-03
|
$377,438
|
$128,329
|
AN, WOOJIN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
Role of Splicing Factors in Breast Cancer
|
5R00CA178206-05
|
$249,000
|
$249,000
|
ANCZUKOW-CAMARDA, OLGA
|
JACKSON LABORATORY
|
|
|
Resource stratified phased implementation frameworks to improve breast healthcare
|
1R13CA224776-01A1
|
$50,000
|
$50,000
|
ANDERSON, BENJAMIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Womens Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S3
|
$175,562
|
$31,601
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
RIP140 as a mediator of Estrogen Receptor action in tumor associated macrophages
|
5F31CA220978-02
|
$35,725
|
$35,725
|
ANDREANO, KAITLYN
|
DUKE UNIVERSITY
|
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-05
|
$303,118
|
$303,118
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$192,282
|
$38,456
|
Annunziata, Christina
|
CCR (NCI)
|
|
|
Quantitative MRI Radiomics of Breast Cancer in Assessment of Malignancy and Response to Therapy
|
1F31CA221193-01A1
|
$26,048
|
$26,048
|
ANTROPOVA, NATALIA
|
UNIVERSITY OF CHICAGO
|
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$90,794
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Regulation and Function of WIP1 Phosphatase and its Role in Tumor Cells
|
ZIA BC 011197
|
$583,055
|
$291,527
|
Appella, Ettore
|
CCR (NCI)
|
|
|
A Novel Values-based Intervention to Increase Endocrine Therapy Adherence among Breast Cancer Survivors
|
1R21CA218723-01A1
|
$207,450
|
$207,450
|
ARCH, JOANNA
|
UNIVERSITY OF COLORADO
|
|
|
PQ2 Obesity-induced fibrocytes promote breast cancer progression
|
1R01CA227542-01
|
$349,988
|
$349,988
|
ARENDT, LISA
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
Cerenkov imaging for in vivo pH determination of the tumor microenvironment
|
5F31CA206453-03
|
$31,442
|
$31,442
|
ARROYO PACHECO, ALEJANDRO
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$34,793
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Total relevant funding to Breast for this search: $574,902,164
|
